SIGA Announces Agreement to Sell TPOXX® to ASEAN Member States

Company Overview - SIGA Technologies, Inc. is a commercial-stage pharmaceutical company focused on health security, including countermeasures for biological threats and therapies for infectious diseases [4] - The company's lead product is TPOXX (tecovirimat), an antiviral drug for treating smallpox [4] Recent Developments - SIGA announced an agreement to expand access to TPOXX for ASEAN member states, coordinated with Meridian Medical Technologies [1][2] - The agreement reflects the use of ASEAN funds to support public health preparedness against potential health events, particularly the Mpox threat [2] Strategic Importance - The ASEAN region, with a population exceeding 600 million and a GDP of $3.6 trillion, represents a significant market for SIGA [2] - This contract establishes a footprint in a densely populated area and lays the groundwork for future activities in Asia [2] Product Information - TPOXX is a novel small-molecule drug approved by the FDA for smallpox treatment in 2018, with an intravenous formulation approved in 2022 [5] - The drug has also received approvals from the European Medicines Agency and the UK's Medicines and Healthcare Products Regulatory Agency for multiple indications, including Mpox and cowpox [5] Market Context - Orthopoxviruses, including smallpox and Mpox, pose a risk to global health security, necessitating effective antiviral solutions [6][7] - Recent Mpox outbreaks in various regions highlight the importance of preparedness and response strategies [6]